Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.38 |
| ▸ | NNMT | P40261 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23767761 | 1.00 | TYMP (0.38) | TYMPNNMTSMN1; SMN2NPEPPSTP53 | |
| SCHEMBL26420156 | 1.00 | TYMP (0.38) | TYMPNNMTSMN1; SMN2NPEPPSTP53 | |
| SCHEMBL26419986 | 0.95 | TYMP (0.40) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26419981 | 0.95 | TYMP (0.40) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26419399 | 0.95 | TYMP (0.40) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26420100 | 0.94 | TYMP (0.38) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26419447 | 0.94 | TYMP (0.38) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL23767773 | 0.94 | TYMP (0.38) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26420042 | 0.94 | TYMP (0.39) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 | |
| SCHEMBL26419432 | 0.94 | TYMP (0.39) | TYMPSMN1; SMN2NPEPPSTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | RNGTT, RNMT, NSUN3 | TYMP 808/4885NNMT 1434/4885SMN1; SMN2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.